Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics presents WTX-124 and WTX-330 clinical data at SITC 2026

Neutral Impact 3 of 5 other

Werewolf Therapeutics released early clinical data for its two INDUKINE candidates, WTX-124 and WTX-330, presented at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. The company said it has aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for WTX-124 and that WTX-330 was well tolerated. The filing contains no financial results, and the data come from small early-stage trials, so shareholders will mainly weigh the programs' future development prospects.

Key points

  • WTX-124 recommended Phase 2 dose set at 18 mg IV Q2W, aligned with the FDA, for monotherapy and combination with pembrolizumab
  • WTX-124 monotherapy produced one durable confirmed complete response in a patient with ICI-resistant cutaneous squamous cell carcinoma, ongoing for approximately three years
  • WTX-330 data from 24 patients showed a confirmed partial response in a patient with gallbladder cancer, per the filing

The filing

CompanyWerewolf Therapeutics, Inc. (HOWL)
Form8-K, current report
Filed with the SECNov 9, 2026, 9:22 AM ET
Accession number0001193125-26-452789

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 9:31 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.